Search for: "TEVA PHARMACEUTICALS, USA"
Results 61 - 80
of 532
Sorted by Relevance
|
Sort by Date
18 Aug 2013, 8:54 pm
Teva Biopharmaceuticals USA, Inc. et al. 2:13-cv-04911; filed August 12, 2013 in the District Court of New Jersey • Plaintiffs: Amgen Inc.; Amgen Manufacturing, Limited • Defendants: Teva Biopharmaceuticals USA, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd. [read post]
24 Jun 2015, 9:59 pm
Teva Pharmaceuticals USA, Inc. [read post]
13 May 2009, 9:50 pm
After Defendant-Appellant Teva Pharmaceuticals USA, Inc. notified P&G of its intent to market a generic version of... [read post]
18 Dec 2009, 9:59 am
Teva Pharmaceuticals USA, Inc. [read post]
28 Jan 2015, 10:00 pm
Watson Pharmaceuticals, Inc., to the Federal Circuit “for further consideration in light of Teva Pharmaceuticals USA, Inc., v. [read post]
1 Jul 2014, 10:00 pm
Teva Pharmaceuticals USA, Inc., the Federal Circuit affirmed the district court’s finding that BMS’s Baraclude® patent is invalid as obvious. [read post]
17 Jan 2016, 8:19 pm
• Defendants: Teva Pharmaceuticals USA Inc.; Teva Pharmaceutical Industries Ltd. [read post]
24 Apr 2016, 9:02 pm
Teva Pharmaceuticals USA Inc. et al. v. [read post]
26 May 2015, 7:06 am
The court denied defendant's motion to reopen the judgment and rejected its argument that Teva Pharmaceuticals USA, Inc. v. [read post]
22 May 2011, 8:41 pm
• Defendant: Teva Pharmaceuticals USA, Inc. [read post]
10 Feb 2017, 10:52 am
February 8, 2017), the Court granted defendant Teva Pharmaceuticals USA, Inc. [read post]
27 Apr 2015, 1:28 pm
Supreme Court on Monday rejected Teva Pharmaceuticals USA Inc.'s request to review a Pennsylvania appellate ruling that federal law did not preempt the product liability claims of thousands of generic Reglan users. [read post]
7 Dec 2021, 8:33 am
: Teva lost its appeal to the CAFC in the case involving mifepristone [here, Korlym, a 300 mg mifepristone tablet ] : Teva faults the Board for, in its view, committing two legal errors. [read post]
27 Jul 2015, 6:07 pm
By Miriam Swedlow Despite overruling the Federal Circuit’s prior practice of reviewing all aspects of patent claim construction de novo, the Supreme Court’s ruling in Teva Pharmaceuticals USA, Inc. v. [read post]
15 Oct 2014, 2:32 pm
The transcript in Teva Pharmaceuticals USA v. [read post]
31 Mar 2014, 6:43 am
The Court has granted Teva Pharmaceuticals USA, Inc. v. [read post]
26 Jan 2010, 9:59 pm
Teva Pharmaceuticals USA, Inc., Proctor & Gamble Co. v. [read post]
15 May 2011, 8:55 pm
• Defendant: Teva Pharmaceuticals USA Inc. [read post]
31 Dec 2015, 8:16 pm
• Defendants: Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd. [read post]
18 Nov 2015, 10:00 pm
Teva Pharmaceuticals USA Inc. and Momenta Pharmaceuticals, Inc. v Amphastar Pharmaceuticals, Inc., the Federal Circuit interpreted two important sections of the infringement statute, 35 USC § 271. [read post]
